Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has announcements × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1 Neoplasms 1

Interventions

pembrolizumab 39 Carboplatin 35 Cisplatin 30 Paclitaxel 24 Nivolumab 22 Pemetrexed 21 Gemcitabine 21 Ipilimumab 16 Dexamethasone 15 Rituximab 14 Fluorouracil 12 Lenalidomide 11 Docetaxel 11 Capecitabine 11 trastuzumab deruxtecan 10 durvalumab 10 atezolizumab 10 Cyclophosphamide 10 olaparib 9 Trastuzumab 8 Prednisone 8 Bevacizumab 8 130-nm albumin-bound paclitaxel 8 zanubrutinib 7 venetoclax 7 daratumumab 7 Bortezomib 7 Bendamustine Hydrochloride 7 osimertinib 6 obinutuzumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡